Product Description
Cancer Molecular Diagnostics: Markets, Strategies and Trends, Volume & Price Forecasts by Cancer Type, Companion Dx and Country with Executive and Consultant Guides 2023 to 2027
“Companion Diagnostics and Liquid Biopsy drive market growth while lowering costs. New cancer diagnostic segments emerging"
Publication date: November 17, 2022
Page count: 412
The cancer molecular diagnostics market is positioned to directly benefit from the explosion in genomics knowledge. Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.
A range of dynamic trends are pushing market growth and company valuations, such as:
- Personalized medicine
- Pharmacogenomics
- Liquid biopsy
- Emergence of new economies with large markets
- Greater understanding of the role of genetic material in disease and health
Based on extensive research, the testing volume data is broken down into price and volume allowing researchers and investors to quickly create informed and reasonable forecasts of demand. In addition customization work, breakouts for particular segments, assistance and support is included free of charge with the corporate license.
We include a special segment on Cancer Companion Diagnostics (CDx), a new segment of the market that is reshaping the industry.
The report includes a complete list of Current 2022 United States Medicare Fee Payment Schedules to help understand test pricing in detail.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School
